The earnings call showed strong sales growth and financial performance, particularly for LUPKYNIS, alongside promising clinical developments with aritinercept. However, regulatory and legal issues present potential challenges.

Company Guidance

During Aurinia Pharmaceuticals' third quarter 2025 conference call, the company reported significant growth in LUPKYNIS sales, with a 27% year-over-year increase, prompting them to raise their 2025 sales guidance to $265 million to $270 million. Total revenue for the quarter reached $73.5 million, marking an 8% increase from the previous year, excluding a $10 million milestone payment from 2024. Net product sales of LUPKYNIS were $70.6 million, up from $55.5 million in 2024, and net income soared 119% to $31.6 million. The company also noted a 162% increase in cash flows from operating activities, reaching $44.5 million. Additionally, Aurinia is advancing aritinercept, a novel biologic, into clinical studies for two autoimmune diseases, following positive Phase I results. The company plans to provide more details on these initiatives in early 2026.

LUPKYNIS Sales Growth

LUPKYNIS sales grew at a rate of 27% for the quarter year-over-year, leading to an increase in sales guidance for 2025 to $265 million to $270 million.

Revenue and Net Income Increase

Total revenue for Q3 2025 was $73.5 million, up 8% from Q3 2024. Net income was $31.6 million, up 119% from $14.4 million in Q3 2024.

Cash Flow Surge

Cash flows from operating activities were $44.5 million, up 162% from $17 million in Q3 2024.

Positive Clinical Developments

Advancement of aritinercept towards clinical studies in 2 autoimmune diseases following positive Phase I results.

LUPKYNIS Efficacy Reinforced

New analyses show LUPKYNIS associated with a 53% reduction in the risk of renal-related events or death.

Aurinia Pharmaceuticals (AUPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AUPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	0.22 / -	0.01	―	―	―
Nov 04, 2025	2025 (Q3)	0.16 / 0.23	0.1	130.00% (+0.13)	―
Jul 31, 2025	2025 (Q2)	0.15 / 0.16	0.01	1500.00% (+0.15)	―
May 12, 2025	2025 (Q1)	0.10 / 0.16	-0.07	328.57% (+0.23)	―
Feb 27, 2025	2024 (Q4)	-0.02 / 0.01	-0.19	105.26% (+0.20)	―
Nov 07, 2024	2024 (Q3)	0.01 / 0.10	-0.09	211.11% (+0.19)	―
Aug 01, 2024	2024 (Q2)	<0.01 / 0.01	-0.08	112.50% (+0.09)	―
May 02, 2024	2024 (Q1)	-0.14 / -0.07	-0.18	61.11% (+0.11)	―
Feb 15, 2024	2023 (Q4)	-0.16 / -0.19	-0.18	-5.56% (-0.01)	―
Nov 02, 2023	2023 (Q3)	-0.17 / -0.09	-0.06	-50.00% (-0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AUPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$13.17	$14.27	+8.35%
Jul 31, 2025	$9.05	$9.24	+2.10%
May 12, 2025	$8.00	$8.12	+1.50%
Feb 27, 2025	$7.95	$7.55	-5.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.